Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
=== Nuclear === In addition to its reported mitochondrial function, some researchers have proposed a very small pool of active nuclear SIRT3 exists. This pool is reported to consist of the long form of SIRT3 and has been suggested to have histone deacetylase activity. The observation that SIRT3 has nuclear activity came from a report that SIRT3 protected cardiomyocytes from stress mediated cell death and that this effect was due to deacetylation of a nuclear factor, Ku-70.
== Continuous production == A common method of increasing efficiency in industrial chromatography is continuous production. There, this is done with SMB (Simulated Moving Bed). In liquid-liquid chromatography, there is no need to simulate a moving bed, as we can move it in reality, and therefore it is TMB, i.e. True Moving Bed. The essence of TMB is to continuously switch the device between ASC and DSC modes, effectively creating a moving bed. This technique is much cheaper than SMB, and its efficiency is not lagging behind. TMB systems are available from mg to tone capacity from LiLiChro.
Cooper was orbiting the Earth every 88 minutes 45 seconds at an inclination of 32.55 degrees to the equator. His scheduled rest period was during orbits 9 through 13. He had a dinner of powdered roast beef mush and some water, took pictures of Asia and reported the spacecraft condition. Cooper was not sleepy and during orbit 9 took some of the best photos made during his flight. He took pictures of the Tibetan highlands and of the Himalayas.
Although no data illustrate the direct association of YTXs and toxicity in humans, issues with regards to the potential health risks of YTXs still stand due to the significant animal toxicity observed, and like other algal toxins present within shellfish, YTKs are not destroyed by heating or freezing. As a result, several countries, including New Zealand, Japan, and those in Europe, regulate the levels of YTXs in shellfish. In 2002, the European Commission placed the regulatory level at 1 μg of YTXs per g (1 mg/kg) of shellfish meat intended for human consumption (Directive 20012/225/EC). Recently, it was shown that yessotoxins can trigger ribotoxic stress.
Sources: en.wikipedia.org
carbide A class of interstitial compounds composed of carbon bonded to a particular metal (usually a large-radius transition metal) in a densely packed crystal lattice, where the carbon atoms occupy interstices between the metal atoms; e.g. tungsten carbide (WC).
Founder, Professionals with Alzheimer's. For services to Charity. Kenneth Salter. For services to the community in Ellesmere Port, Cheshire. Cheryl Anne Sanderson. For services to Cancer Patients in Barnsley, South Yorkshire. David Saunders. For services to the community in Middlesbrough, North Yorkshire. Annie Groat Scott. For services to the community in Westray, Orkney. Pamela Mary Joyce Scull (Pamela Wingfield). Founder Principal, Wingfield School of Ballet and Dance. For services to Dance and to the community in Bristol. Sanjay Shambhu. Councillor, South Gloucestershire Council and Chair, BAME Conservatives. For Political Service. John Frederick Sharman. For services to the community in Peterborough, Cambridgeshire. Janice Sheward. Director, Cancer United. For services to People with Cancer in West Sussex. Darren Keith Sims. Founder, Daz's Rock 4 Charity. For Charitable Fundraising for Disabled and Disadvantaged Young People. Ian Robert Skinner. For services to the community in Sidmouth and the Sid Valley, Devon. Angela Ann Smith. Lately Deputy Manager, Process Controls Team, Defence Business Services. For services to Defence and to Charity. Carl Smith. Advanced Paramedic in Critical Care, East of England Ambulance Service NHS Trust, Head, Clinical Development for Emergency and Critical Care, College of Paramedics and Firefighter, Norfolk Fire and Rescue Service. For services to the NHS and to Fire and Rescue. Cheryl Barbara Smith. Leader, Girlguiding Cornwall. For services to Young People. John Alexander Alister Smyth.
=== 1971-2000 === In 1971, Revlon acquired DCL BioMedical, a clinical laboratory business founded in 1968. In 1974, it changed its name to National Health Laboratories Incorporated. By 1977, it operated clinical testing laboratories in 13 cities and maintained auxiliary service centers and satellite laboratories in 15 other cities. In 1978, it acquired American Biomedical Corporation, giving it operations in the Southwestern United States and data processing technology. In 1985, Revlon was acquired by Ronald Perelman. Revlon divested its other businesses and a major stake in the company was acquired by MacAndrews & Forbes. In 1988, National Health Laboratories became a public company via an initial public offering on the NASDAQ exchange. In 1989, the company generated revenue of about US$400 million, with about US$70 million in earnings. In the early 1990s, worries about malpractice lawsuits led doctors to conduct more clinical testing before diagnosing, which increased business for the company. In 1990, the company's revenues reached US$500 million, with over US$70 million in earnings. In 1991, National Health Laboratories moved its listing from the NASDAQ to the New York Stock Exchange. In June 1992, the company offered to acquire Damon Corporation for $260 million in cash and stock. However, the company was outbid by Corning Inc., which acquired Damon for $370 million. By 1993, the company had 22 major laboratories. On March 8, 1994, National Health Laboratories Inc. reorganized as a holding company, National Health Laboratories Holdings Inc.
== Analogs == Structural analogs of desmethylprodine with different N-substituents than a methyl group on the piperidine have been investigated. Several of these have significantly greater in vitro potency compared to desmethylprodine.
== Tissue culture == In many cases, creation of functional tissues and biological structures in vitro requires extensive culturing to promote survival, growth and inducement of functionality. In general, the basic requirements of cells must be maintained in culture, which include oxygen, pH, humidity, temperature, nutrients and osmotic pressure maintenance. Tissue engineered cultures also present additional problems in maintaining culture conditions. In standard cell culture, diffusion is often the sole means of nutrient and metabolite transport. However, as a culture becomes larger and more complex, such as the case with engineered organs and whole tissues, other mechanisms must be employed to maintain the culture, such as the creation of capillary networks within the tissue.
Sources: en.wikipedia.org
=== Language === Marain is the Culture's shared constructed language. The Culture believes the Sapir–Whorf hypothesis that language influences thought, and Marain was designed by early Minds to exploit this effect, while also "appealing to poets, pedants, engineers and programmers". Designed to be represented either in binary or symbol-written form, Marain is also regarded as an aesthetically pleasing language by the Culture. The symbols of the Marain alphabet can be displayed in three-by-three grids of binary (yes/no, black/white) dots and thus correspond to nine-bit binary numbers. Related comments are made by the narrator in The Player of Games regarding gender-specific pronouns, which Marain speakers do not use in typical conversation unless specifying one's gender is necessary, and by general reflection on the fact that Marain places much less structural emphasis on (or even lacks) concepts like possession and ownership, dominance and submission, and especially aggression. Many of these concepts would in fact be somewhat theoretical to the average Culture citizen. Indeed, the presence of these concepts in other civilisation signify the brutality and hierarchy associated with forms of empire that the Culture strives to avoid. Marain itself is also open to encryption and dialect-specific implementations for different parts of the Culture. M1 is basic Nonary Marain, the three-by-three grid. All Culture citizens can communicate in this variant. Other variants include M8 through M16, which are encrypted by various degrees, and are typically used by the Contact Section.
=== Environmentally friendly alternatives === Reusable RMW or sharps containers reduce the amount of plastic sent to landfills and CO2 emissions. Non-incineration treatment includes four basic processes: thermal, chemical, irradiative, and biological. The main purpose of the treatment technology is to decontaminate waste by destroying pathogens. Modern technology invented mechanics that would allow medical professionals and hospitals to dispose medical waste in an environmentally friendly way, such as autoclaving, plasma pyrolysis, gasification, chemical methods, and microwave irradiation. These alternatives are also highly versatile and can be used for all different types of waste. An autoclave, similar to a pressure cooker, uses high-temperature steam to penetrate waste material and kill micro-organisms. Autoclave treatment has been recommended for microbiology and biotechnology waste, waste sharps, soiled and solid wastes. Microwave irradiation is based on the principle of generation of high-frequency waves. These waves cause the particles within the waste material to vibrate, generating heat and killing the pathogens from within. A simple yet effective method is chemical disinfection: 1% hypochlorite can kill thriving bacteria. Plasma pyrolysis is an environment-friendly mechanism, which converts organic waste into commercially useful byproducts. The intense heat generated by the plasma enables it to dispose all types of waste including municipal solid waste, biomedical waste and hazardous waste in a safe and reliable manner.
== Regulation == The flux of the entire pathway is regulated by the rate-determining steps. These are the slowest steps in a network of reactions. The rate-limiting step occurs near the beginning of the pathway and is regulated by feedback inhibition, which ultimately controls the overall rate of the pathway. The metabolic pathway in the cell is regulated by covalent or non-covalent modifications. A covalent modification involves an addition or removal of a chemical bond, whereas a non-covalent modification (also known as allosteric regulation) is the binding of the regulator to the enzyme via hydrogen bonds, electrostatic interactions, and Van der Waals forces. The rate of turnover in a metabolic pathway, also known as the metabolic flux, is regulated based on the stoichiometric reaction model, the utilization rate of metabolites, and the translocation pace of molecules across the lipid bilayer. The regulation methods are based on experiments involving 13C-labeling, which is then analyzed by nuclear magnetic resonance (NMR) or gas chromatography–mass spectrometry (GC–MS)–derived mass compositions. The aforementioned techniques synthesize a statistical interpretation of mass distribution in proteinogenic amino acids to the catalytic activities of enzymes in a cell.
=== Alcohol use disorder === Naltrexone has been best studied as a treatment for alcoholism, or alcohol use disorder (AUD). Naltrexone has been shown to decrease the quantity and frequency of alcohol consumption by reducing the release of dopamine, a neurotransmitter associated with the euphoria that often accompanies alcohol use. Studies comparing naltrexone to a placebo have shown a small but statistically significant decrease in relapse likelihood. Its overall benefit has been described as "modest". Acamprosate may be more effective for AUD management overall, while naltrexone may decrease the desire for alcohol to a greater extent. A method pioneered by scientist John David Sinclair (dubbed commercially the "Sinclair Method") in the 1980s advocates "pharmacological extinction" of problem drinking behavior by administering naltrexone alongside controlled alcohol consumption. In effect, he argues that naltrexone-induced opioid antagonism sufficiently disrupts reflexive reward mechanisms inherent in the consumption of alcohol and, given enough repetition, will dissociate positive associations formerly made with the consumption of alcohol. A 2001 review of eight studies of naltrexone treatment in the setting of AUD concluded that, "although all found benefits from naltrexone with the coping therapy, none of them found any significant benefit of naltrexone over placebo when combined with support for abstinence."
Oxymorphazone is an opioid analgesic drug related to oxymorphone. Oxymorphazone is a potent and long acting μ-opioid agonist which binds irreversibly to the receptor, forming a covalent bond which prevents it from detaching once bound. This gives it an unusual pharmacological profile, and while oxymorphazone is only around half the potency of oxymorphone, with higher doses the analgesic effect becomes extremely long lasting, with a duration of up to 48 hours when administered intraventricularly. However, tolerance to analgesia develops rapidly with repeated doses, as chronically activated opioid receptors are rapidly internalised by β-arrestins, similar to the results of non-covalent binding by repeated doses of agonists with extremely high binding affinity such as lofentanil.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.